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Edited by Sandro SonninoAbstract The prion protein (PrP) peptide 106–126 forms
amyloid aggregates in vitro and this sequence is speculated to
be involved in the formation of amyloid ﬁbrils by the abnormally
folded PrP protein (PrPSc) found in spongiform encephalopa-
thies. It is shown here by incubation experiments in water using
Thioﬂavin T (ThT) as a ﬂuorescent probe for amyloid formation
that changes in C-terminal charge, oxidation state and confor-
mational stabilisation lead to large changes in amyloid forming
behaviour (amyloidogenicity) of this peptide. Amyloid formation
is favoured by a charged C-terminus and is strongly inhibited by
oxidation. Furthermore, cationic dendrimers are shown to
perturb peptide ﬁbrillation in a process dependent on the nature
of the charged groups on the dendrimer surface.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The prion protein (PrPC) is a constitutively expressed
membrane glycoprotein mainly found on the surface of neu-
ronal cells and involved in the development of transmissible
spongiform encephalopathy (TSEs), in which protein deposits
containing an abnormally folded isoform of PrP (PrPSc) are
invariably found [1]. PrPSc is insoluble, highly protease resis-
tant, and contains an increased proportion of amount of
b-strands compared to PrPC [2]. As deposition of PrPSc is ac-
companied by neuronal cell death, there has been considerable
interest in determining the correlation between folding variants
and the possible neurotoxicity of PrP [3].
A region located near the N-terminal of the protease-resis-
tant PrPSc has attracted interest, as the corresponding peptide
(PrP106–126) has been shown to be amyloidogenic and neu-
rotoxic [4,5]; interestingly, neurotoxicity depends on the ex-* Corresponding author. Fax: +45-72346001.
E-mail address: pmhh@dfvf.dk (P.M.H. Heegaard).
Abbreviations: PrP, prion protein; PrP106–126, prion protein peptide
106–126; PPI, poly(propylene imine); ThT, thioﬂavin T; TSE, trans-
missible spongiform encephalopathy; PBS, phosphate-buﬀered saline;
mw, molecular weight
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doi:10.1016/j.febslet.2004.09.073pression of endogenous PrP [6] as is also the case for the
neurotoxicity and transmissibility of PrPSc [7].
Tagliavini et al. [4] found that PrP106–126 readily formed
amyloid ﬁbrils similar to those seen in Gerstmann–Str€aussler–
Scheinker disease, a rare heritable TSE in which the amyloid
deposits contain a PrP fragment of approximately 100 residues
(amino acids 58-approx. 150). Forloni et al. [5] showed this
peptide to be toxic in vitro against rat hippocampal neurons,
treated for several days with the peptide (chronic exposure),
and later Ettaiche et al. [8] demonstrated in vivo toxicity of
aged 106–126 peptide in a rat retinal model.
Fibril formation is thought to proceed through a slightly
unfolded state (a ‘‘molten globule’’ like state) of the protein in
question, followed by a nucleation state (soluble protoﬁbril
formation) and ending up in aggregation of ﬁbrils into long,
unbranched amyloid ﬁbrils with a generic ‘‘cross’’-b-sheet
structure [9] with a characteristic ability to bind certain dyes,
including Congo Red and the ﬂuorescent dye Thioﬂavin T
(ThT) [10].
Molecular modelling at pH 7 indicates that PrP106–126 has
a preference for b-sheet structure [11], but it can also be as-
signed a more random coil structure incorporating a-helical
elements. A similar peptide, PrP109–122, was predicted by
others to be a-helical [12]. However, the 106–126 sequence is
part of the unstructured, N-terminal half of the PrPC molecule,
next to the globular part [13]. In PrPSc, 106–126 is part of the
protease-resistant core of the protein (approx. 90–231 [14]).
The N-terminal, unstructured part of the PrP protein belongs
to the recently described class of ﬁbrillation-prone natively
unfolded proteins [15].
Selvaggini et al. [16] and Salmona et al. [14] used circular
dichroism and turbidimetry to study structure and ﬁbril for-
mation potential of several PrP106–126 variants, including the
carboxamide, and histidine 111 substitutions (D-histidine, ala-
nine and lysine) and a variant combining anA117V substitution
with the carboxamide. A charge at position 111 was found to be
important to retain adequate solubility to ensure ﬁbrillation.
The free peptide (C-terminal acid) was found to be much more
prone to b-structure formation than the carboxamide, but the
A177V substitution (alanine 177 substituted by valine) in the
peptide amide rendered the amide more b-like. A similar ﬁbril-
promoting eﬀect of a free C-terminal carboxylic acid was found
by Terzi et al. [17] with the Ab-peptide of Alzheimer’s plaques.
Furthermore, b-sheet content was enhanced at low pH (5)
compared to neutral pH and while some secondary structureblished by Elsevier B.V. All rights reserved.
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was detected in deionised water [14,15]. Similarly, DeGoia et al.
[18] found predominantly b-structure in 200 mM phosphate,
pH 5.0, combination of b and random coil in both phosphate at
pH 7.0 and deionised water at pH 5, while the peptide exhibited
least structure in pure water. These studies were performed on
freshly prepared solutions of peptide in the mg/ml range. In-
terestingly, the aggregation property of PrP106–126 was greater
at pH 7 than at pH 5 as assessed by turbidity after 24 h of
incubation [14]. Also, Florio et al. [19] described a highly
structured peptide variant (G114A, G119A) that formed pro-
toﬁbrils, but never went on to form amyloid ﬁbrils.
The ‘‘hydrophobic core’’ AGAAAAGAVV was found to be
indispensable for amyloidogenicity of the peptide as any of a
number of substitutions (S for V or A) in this sequence ren-
dered PrP106–126 non-amyloidogenic (and non-neurotoxic) as
was also the case with neighbouring peptides not comprising
the whole core sequence [20,21].
Thus, amyloidogenicity of these PrP peptides depends on a
ﬁne balance between solubility and insolubility and between
structure forming tendency and ﬂexibility.
We observed that synthetic PrP106–126 preparations often
contained a substantial amount of spontaneously oxidised
peptide (see below) and it was, therefore, relevant to study if
oxidation had any eﬀect on the ﬁbrillation behaviour of the
peptide. Although the peptide contains two oxidation sensitive
methionines and although PrP has often been speculated to be
involved in oxidative processes as part of its normal function
[22], no data on this have to our knowledge been reported
previously. Oxidation was found to have profound eﬀects on a
number of other polypeptides involved in neurodegenerative
diseases. For example, a-synuclein, the small presynaptic pro-
tein associated with Parkinson’s disease, lost its ability to form
amyloid ﬁbrils when its four methionines were oxidised [15] and
the Ab-peptide of Alzheimer’s disease,when oxidised at the
methionine residue, also could no longer form amyloid ﬁbrils
[23,24]. Here, deliberately oxidised PrP106–126 was analysed in
the ThT assay for amyloid ﬁbrillation capacity compared to the
unmodiﬁed peptide. Furthermore, we compared the ﬁbrillation
behaviour of PrP106–126 with the amide form of the peptide,
with a covalently coupled parallel dimer of the peptide
(PrP106–126 dibranch) and with a structure-relaxed form of the
peptide (PrP106–126 RG2). We also investigated the eﬀect of a
cationic dendrimer that was found previously to be able to
solubilise certain PrPSc aggregates [25–27], in addition to a new
type of dendrimer modiﬁed with surface guanidinium groups.
Amyloid ﬁbril formation may be an inherent trait of all
peptides, favoured by speciﬁc conditions of pH, salt and organic
solvents [28–30]. Such generic amyloid ﬁbrils may all be cyto-
toxic especially in their early, protoﬁlament stage (soluble, non-
ﬁbrillar aggregates [31]). In the present study, the ﬁbrillation
behaviour of the PrP106–126 peptide and its molecular variants
was studied in pure water to exclude eﬀects of pH and salts and
using ThT binding as a probe for amyloid ﬁbril formation.2. Materials and methods
2.1. Peptides
Peptides were synthesised by solid phase Fmoc-based synthesis using
chlorotrityl resins for peptide acids and resins with the modiﬁed Rink
linker for peptide amides (Novabiochem).The dibranched peptide amide was prepared by sequential synthesis
on a Rink-coupled C-terminal lysine that was selectively deprotected
ﬁrst at its a-amino group allowing synthesis of the ﬁrst strand of
PrP106–126, which was then N-acetylated. Second, the e-amino group
was deprotected by removing the methyltrityl (Mtt) protecting group
with 1% triﬂuoroacetic acid allowing for the synthesis of the second
strand. The acid dibranched peptide was prepared using K(4,4-di-
methyl-2,6-dioxocyclohex-1-ylidene)ethyl – (Dde-) for the ﬁrst strand
synthesis ending with N-acetylation. K(Dde) was then deprotected
with 2% hydrazine in N-methyl pyrrolidone and used for coupling of a
presynthesised molecule of PrP106–126 (prepared on chlorotrityl resin
and used in its protected state) by uronium chemistry [32].
After synthesis, cleavage by triﬂuoroacetic acid and work-up were
performed as described elsewhere [32]. Peptides were analysed by re-
verse phase (C5) HPLC-MS (Shimadzu LC20) and, if necessary, pu-
riﬁed by preparative reverse phase chromatography on Lichrosorp C18
(Merck).
Peptides were kept at minus 20 C as freeze-dried powders until use.
The following peptides were used in this work:
PrP106–126
KTNMKHMAGAAAAGAVVGGLG
(human PrP106–126, expected mw: 1912.3)
PrP106–126 amide
KTNMKHMAGAAAAGAVVGGLG – amide
(expected mw: 1911.3)
PrP106–126 control
LVGAHAGKMGANTAKAGAMVG
(scrambled sequence, expected mw: 1912.3)
Prp106–126 RG2
KTNMKHMAGAAAAGAVVGGLGRGGRGGRGG
(expected mw: 2722)
PrP106–126 dibranched
(expected mw: 3976)
PrP106–126 amide dibranched
(expected mw.: 3975)
All peptides are acids unless otherwise speciﬁed.
Oxidation was performed by incubation of 2.5 mM peptide in
phosphate-buﬀered saline (PBS) with 200 ll hydrogen peroxide
(Merck, 30%) per 1 ml peptide solution for 20 min at room tempera-
ture followed by size exclusion chromatography (desalting) on a PD10
column from Amersham Pharmacia using 10% acetic acid as the sol-
vent, following the instructions from the manufacturer. Oxidation
(100%) was conﬁrmed by HPLC-MS showing a mass increase of 32
corresponding to the oxidation of methionine side chains to sulfoxides.
The oxidised peptide eluted slightly earlier than the unmodiﬁed peptide
on the reverse phase column (see Fig. 1).
2.2. Dendrimers
Second generation poly(propylene imine) (PPI) dendrimer was
obtained from Aldrich (DAB-Am-8). The surface amines of the
dendrimer were converted to guanidines by reaction with 1,3-diBoc-2-
methylisothiourea (Fluka), followed by deprotection with 95% aque-
ous triﬂuoroacetic acid. The deprotected guanidinium derivatised
dendrimer was precipitated with diethyl ether, followed by removal of
the ether supernatant. The residue was dissolved in water and freeze-
dried, giving the dendrimer as a white solid. The molecular mass of the
modiﬁed dendrimer was veriﬁed by matrix-assisted laser desorption
Acetyl-KTNMKHMAGAAAAGAVVGGLG
KTNMKHMAGAAAAGAVVGGLGK
Acetyl-KTNMKHMAGAAAAGAVVGGLG
KTNMKHMAGAAAAGAVVGGLGK-amide
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Fig. 1. HPLC-MS analysis of PrP106–126 peptide raw product (A) and a raw product deliberately oxidised by H2O2 (B). The two main products seen
in the HPLC (220 nm) trace of the raw product (A) are scanned for m/z identifying a main peak m/z of 638 (deduced mw.: 1911) and a m/z of the
‘‘shoulder’’ of 644 (deduced mw.: 1929). The deliberately oxidised raw product (B) shows one main peak with a m/z of 649 (deduced mw.: 1944).
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shown). The structures of unmodiﬁed PPI dendrimer and guanidino-
derived dendrimer are shown in Fig. 3A.
2.3. ThT – assay for amyloid ﬁbril formation
Peptides were dissolved at 2 mg/ml (approximately 1 mM for all
peptides except the dibranch peptides where this corresponds to 0.5mM) in water and allowed to incubate at room temperature with slight
agitation in the presence of 20 lM ThT (Sigma T3516, 1 mM stock
solution in water), reading the ﬂuorescence each day at 485 nm using
an excitation wavelength of 440 nm (with a Spectra Fluor Plus mi-
croplate Fluorometer from Tecan). Readings were normalised to the
same gain setting to allow comparisons from sample to sample. When
comparing between diﬀerent plates, values were furthermore corrected
Fig. 2. ThT-binding of PrP106–126 variants. (A) Concentration de-
pendence of ThT ﬂuorescence (PrP106–126 and scrambled control
peptide) as analysed after 2 days of incubation. (B) Eﬀect of incubation
period at 2 mg/ml of PrP106–126, oxidised PrP106–126 and scrambled
control peptide. (C) ThT ﬂuorescence after 7 days of incubation at 2
mg/ml of the PrP106–126 variants indicated (see text) as compared to
the unmodiﬁed PrP106–126 peptide (100%). All incubations were
performed at room temperature with gentle agitation in 100 ll water.
Error bars indicate standard deviations of double determinations.
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ded to solutions of peptides (1 mg/ml) and ThT (20 lM) at 20 lg/ml
and coincubated throughout.3. Results and discussion
Oxidation of PrP106–126 occurred spontaneously during
solid phase synthesis and work-up and was usually encoun-
tered at a level of around 20–30% of the total peptide (see
Fig. 1A). The oxidised peptide had a lower retention time in
reverse phase HPLC and an increased molecular weight
roughly corresponding to the conversion of one methionine
residue into methionine sulfoxide; peptide products with both
methionines converted could also be detected but at a lower
level (not shown). The peptide could be oxidized with hydro-
gen peroxide to yield the peptide containing two methionine
sulfoxides (Fig. 1B); this preparation was used as the oxidised
peptide in the ThT experiments. The oxidised peptide in turn
could be reduced by dithiothreitol to yield the fully reduced
peptide (not shown).
Thus, PrP106–126 is prone to oxidation during its produc-
tion resulting in the formation of a peptide containing one to
two methionine sulfoxide residues. This is not an uncommon
side-reaction during production of synthetic peptides con-
taining methionines and has in fact been speciﬁcally reported
for the Alzheimer peptide, Ab [33], but no such oxidation
products of PrP106–126 have to our knowledge been reported
previously.
The ThT assay clearly indicated the formation of amyloid
ﬁbrils during incubation of the PrP106–126 peptide at con-
centrations of 2 and 1 mg/ml in water, while at lower peptide
concentrations amyloid ﬁbril formation was negligible after 2
days of incubation (Fig. 2A); ﬁbrils formed most readily at
room temperature with gentle agitation, while higher temper-
ature (37 C) leads to slower ﬁbril formation (not shown);
there was no discernible lag phase and a plateau was only
reached late in the observation period (at day 23, Fig. 2B). The
absence of a lag phase can be explained by the lack of initial
structure in the peptide and consequently the absence of an
initial rate limiting unfolding step. The sequence-scrambled
control peptide did not show any ThT binding at any time and
the oxidised peptide reached only around 10% of the ThT
ﬂuorescence observed with the unmodiﬁed peptide (Fig. 2B
and C). The strongly decreased ThT binding of the oxidised
peptide indicates that it is less amyloidogenic than the un-
modiﬁed peptide. This is supported by Fig. 2B, where it can be
seen that the ThT binding over time of the oxidised peptide
evolves with a diﬀerent slope than the ThT binding of the
unmodiﬁed peptide. Thus, although it cannot be totally ex-
cluded that oxidised PrP106–126 simply binds less ThT by it-
self, the decreased ThT binding is probably due to a decreased
tendency of the oxidised peptide to form amyloid ﬁbrils.
This is of interest as we observed spontaneous formation of
oxidised peptide during synthesis and work-up of PrP106–126
at around 20–30% of the raw product depending on the batch
(Fig. 1A) (vide supra). Thus, diﬀerent proportions of oxidised
peptide molecules in diﬀerent batches of PrP106–126 would
lead to diﬀerent ﬁbrillation tendencies. This might be one
reason for why reproducing ﬁbrillation and biological activity
of diﬀerent PrP106–126 preparations have proved to be diﬃ-
cult [6,34]. It could also be tempting to speculate that the de-
gree of oxidation of the 106–126 sequence could inﬂuence the
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Fig. 3. (A) PPI second generation underivatised dendrimer (dendrimer
1, top) and PPI dendrimer derivatised with guanidinium surface
groups (dendrimer 2, bottom). (B) Eﬀect of dendrimer 1, dendrimer 2
and guanidinium hydrochloride on the ThT ﬂuorescence of PrP106–
126. Peptide was incubated at 1 mg/ml in deionised water with 20 lg/
ml dendrimer or 2.5 M guanidinium hydrochloride.
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lation tendency of the oxidised peptide is most probably a
consequence of the increased hydrophilicity of the more polar
sulfoxide side chain of oxidised methionine, rendering hydro-
phobic peptide-to-peptide interactions less favourable. Similar
eﬀects of oxidation were reported previously for the Ab pep-
tide of Alzheimer’s disease and for the small protein a-synuc-
lein of Parkinson’s disease which were both unable to form
amyloid ﬁbrils after deliberate and complete oxidation of the
methionines [15,23,24], correlating with loss of ability to form
b-sheets. Interestingly, the non-ﬁbrillar, oxidised Ab peptide
still retained neurotoxicity [23,24].
Other spontaneous modiﬁcations of the PrP106–126 peptide
have been demonstrated, e.g., deamidation and isomerisation
of N108 which occurs upon aging [35], but no biological or
biophysical eﬀects of such modiﬁcations were demonstrated. A
similar modiﬁcation was, however, enough to make a 23
amino acid leucine-rich repeat peptide loose its ability to form
b-structure and to form ﬁbrils [36].
In addition to the clearly relevant oxidation product of
PrP106–126, which represents a peptide variant with increased
hydrophilicity but no change in charge, a number of other
molecular variants of the peptide were studied, including the
C-amidated peptide (decreasing charge and hydrophilicity), a
dibranched peptide construct (increased conformational sta-
bility) and a variant of the peptide carrying an additional,
conformationally destabilising sequence with additional char-
ges ((RG2)3).
The C-amide form of 106–126 was not amyloidogenic under
the conditions used here (Fig. 2C); this is in line with earlier
results on PrP106–126 [14] and the Ab-peptide [17], where a
signiﬁcant decrease in b-structure and ﬁbrillation tendency was
observed upon amidation of the C-terminal carboxyl group. In
those studies, the ﬁbrillation tendency was not abolished
completely. This could be due to the fact that the incubations
were performed in phosphate buﬀer and not in water as in the
present study; we do in fact ﬁnd some ThT binding of
the peptide amide, and a general increase in ThT binding of all
the peptides studied when performing the incubation in
200 mM phosphate, most at pH 7.0 and less at pH 5.0 (not
shown). The increased tendency of amyloid formation of the
acid form of the peptide was used by Salmona et al. [14] to
support a model for organisation of the peptide molecules into
anti-parallel b-sheets, stabilised by the C-terminal anion.
The dibranched peptide construct of PrP106–126 was also
studied, both with a C-terminal carboxylic acid group and in
its C-amide form, and in this case, surprisingly, only the amide
showed a tendency for ﬁbril formation while the acid form did
not show any ThT binding whatsoever (Fig. 2C). Thus, pre-
organisation of PrP106–126 into parallel dimers in the di-
branched construct increased amyloidogenicity of the peptide
amide from zero, while it abolished the marked amyloidoge-
nicity of the free peptide acid. This suggests that while the
optimal packing mode for the free peptide acid is probably an
antiparallel arrangement stabilised by electrostatic interactions
(see above), this is not possible with the dibranched molecule.
On the other hand, parallel packing of the peptide amide is not
as disfavoured as it is for the peptide acid, and as antiparallel
packing of dibranched molecules furthermore is unfavourable,
the dibranched peptide amide could be speculated to form
amyloid ﬁbrils by parallel stacking. Parallel packing is poten-
tially possible for the PrP106–126 amide, but it obviously doesnot occur spontaneously without pre-arranging the peptide
amide. Thus, the preferred packing mode of PrP106–126 is
dependent on both charge and covalent preorganisation of the
132 P.M.H. Heegaard et al. / FEBS Letters 577 (2004) 127–133peptide. This could be important for the ability of 106–126
segment in PrP, which is by deﬁnition an amide and partly
conformationally restricted, to contribute to the aggregation
tendency and amyloidogenicity of PrPSc and there is in fact
some evidence in favour of a parallel packing of b-strands
involving 106–126 in PrPSc [37]. Taken together, this indicates
that the monomeric PrP106–126 acid arranges itself into an-
tiparallel b-sheets, however, this might not be the biologically
relevant stacking arrangement.
The RG2-modiﬁed peptide lost most of its ability to bind
ThT (Fig. 2C), indicating that this extension of the peptide had
some eﬀect on the ﬁbrillation capacity of the peptide; charge
repulsion would seriously destabilise a parallel packing of
peptide molecules. If molecules were organised in an antipar-
allel fashion, the structure ‘‘relaxing’’ ability of the RG2 might
preclude ﬁbril formation, indicating that some structural def-
inition is important for the ability of the peptide to form
amyloid ﬁbrils.
Finally, it was found that a modiﬁed dendrimer with highly
cationic guanidinium surface groups (dendrimer 2, Fig. 3A)
dramatically decreased ﬁbril formation at 20 lg/ml when
coincubated with PrP106–126 (1 mg/ml) and ThT, while the
unmodiﬁed dendrimer carrying surface amino groups had no
destabilising eﬀect but on the contrary seemed to support ﬁbril
formation (dendrimer 1, Fig. 3A and B). The ﬂuorescence of
ThT alone incubated with dendrimers was not above back-
ground and the dendrimers did not quench the ﬂuorescence of
ThT itself (not shown).
The eﬀect of 20 lg/ml guanidino-modiﬁed dendrimer was
similar to the eﬀect of 2.5 M guanidinium hydrochloride.
These incubations were performed in water where the gua-
nidino-modiﬁed dendrimer is fully charged, while the un-
modiﬁed dendrimer is much less so due to the lower pKa of
the amino group. Thus, the ﬁbrillation inhibiting eﬀect must
be ascribed to the positive charge on the surface of the gua-
nidino-modiﬁed dendrimer. This is in accordance with Sup-
attapone et al. [25], who found that charging the dendrimer
by low pH (5.0) was necessary to achieve an unfolding eﬀect
on PrPSc. Thus, we ﬁnd an eﬀect of cationic dendrimers on
the PrP106–126 peptide that is similar to the previously de-
scribed eﬀect on PrPSc [25–27], indicating the importance of
the 106–126 sequence in the folding and aggregation events of
PrP.
In contrast to these ﬁndings, Goers et al. [38] found that a
variety of polycations accelerated the formation of a-synuclein
ﬁbrils. However, as a-synuclein belongs to the group of na-
tively unfolded proteins, the eﬀects of polycations are limited
to an organisational role in the formation of rate-limiting ﬁ-
brillation nuclei; whether polycationic dendrimers also could
have such eﬀects with PrPSc aggregates or PrP106–126 ﬁbrils is
not known, but there is an indication in Fig. 3B that the un-
modiﬁed dendrimer with amino surface groups actually pro-
motes ﬁbrillation of PrP106–126.
The dendrimer eﬀect on PrP106–126 resembles a denaturing
or solubilising eﬀect similar to that of chaotropic salts like
guanidinium chloride and urea and it is, therefore, tempting to
propose that the eﬀect of dendrimers on PrPSc aggregates is
purely solubilising and does not involve speciﬁc binding be-
tween the protein and the dendrimer as was proposed previ-
ously [25]. This in turn implies that hydrophobic interactions
are the driving force behind the formation of PrP106–126
amyloid ﬁbrils.It will be interesting to study the neurotoxicity of peptide
variants with decreased amyloidogenicity, e.g., the peptide
amide and the oxidised peptide, which chemically and struc-
turally are very diﬀerent from each other. The neurotoxicity of
PrP is going to be a complicated issue as other parts of PrP
have been shown to exhibit another type of neurotoxocity
being independent of both peptide aggregation state and of
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